# A Study of LW231 to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Volunteers and Participants With Chronic Hepatitis B Virus Infection

> **NCT06311734** · PHASE1 · COMPLETED · sponsor: **Shanghai Longwood Biopharmaceuticals Co., Ltd.** · enrollment: 119 (actual)

## Conditions studied

- Chronic Hepatitis B

## Interventions

- **DRUG:** LW231 tablets
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06311734
- **Lead sponsor:** Shanghai Longwood Biopharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-21
- **Primary completion:** 2024-01-01
- **Final completion:** 2024-03-18
- **Target enrollment:** 119 (ACTUAL)
- **Last updated:** 2024-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06311734

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06311734, "A Study of LW231 to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Volunteers and Participants With Chronic Hepatitis B Virus Infection". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06311734. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*